Dirk Schadendorf

Cited by

	All	Since 2019
Citations	200837	121350
h-index	176	138
i10-index	878	647

26000

13000

6500

19500

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024712 800 868 1045 1073 1006 1073 1067 1102 1317 1607 2500 3848 5341 6658 8752 11036 12394 13740 17537 22538 25448 24651 23205 7712

Public access

View all

254 articles

23 articles

available

not available

Based on funding mandates

Co-authors

Selma UgurelProfessor of Medicine, University of Duisburg-EssenVerified email at uk-essen.de
Paolo A. AsciertoIstituto Nazionale Tumori Fondazione "G. Pascale", Napoli, ItalyVerified email at istitutotumori.na.it
Georgina V LongMelanoma Institute Australia, The University of Sydney and Royal North Shore HospitalVerified email at sydney.edu.au
Jochen Sven Utikal, MDProfessor for Dermatooncology, German Cancer Research Center and University Medical Center MannheimVerified email at dkfz.de
James LarkinRoyal Marsden Hospital / Institute of Cancer Research, London, UKVerified email at rmh.nhs.uk
Helen GogasNational and Kapodistrian University of AthensVerified email at med.uoa.gr
Antoni RibasUCLAVerified email at mednet.ucla.edu
Alexander EGGERMONTPrincess Maxima Center & University Medical Center Utrecht, Netherlands alexander.eggermontVerified email at prinsesmaximacentrum.nl
Thomas EigentlerDepartment of Dermatology, Venereology and Allergology, Charité BerlinVerified email at charite.de
Victoria AtkinsonUniversity of Queensland, Princess Alexandra Hospital, Gallipoli Medical Research FoundationVerified email at health.qld.gov.au
Joachim DissemondUniversity Duisburg-EssenVerified email at uk-essen.de
Richard KeffordMacquarie UniversityVerified email at mq.edu.au
Susanne HornPhDVerified email at helmholtz-munich.de
Stefan B. EichmüllerGerman Cancer Research Center (DKFZ)Verified email at dkfz.de
Blank cNetherlands Cancer InstituteVerified email at nki.nl
Titus J. BrinkerDigital Biomarkers for Oncology, German Cancer Research Center (DKFZ), Heidelberg, GermanyVerified email at DKFZ.de
Stephan GrabbeProfessor für Dermatologie, Universitaetsmedizin MainzVerified email at unimedizin-mainz.de
Rajmohan MuraliMemorial Sloan Kettering Cancer CenterVerified email at mskcc.org
Rajiv KumarGerman Cancer Research CenterVerified email at dkfz.de
Grant McArthurPeter MacCallum Cancer CentreVerified email at petermac.org

Dirk Schadendorf

Professor für Dermatologie, University Hospital Essen; University of Duisburg-Essen

Verified email at uk-essen.de

Cancer melanoma translational research dermatology


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
Improved survival with ipilimumab in patients with metastatic melanoma FS Hodi, SJ O'day, DF McDermott, RW Weber, JA Sosman, JB Haanen, ... New England Journal of Medicine 363 (8), 711-723, 2010	17028	2010
Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011	9056	2011
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015	7866	2015
Nivolumab in previously untreated melanoma without BRAF mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015	6008	2015
The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018	4355	2018
Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells FO Nestle, S Alijagic, M Gilliet, Y Sun, S Grabbe, R Dummer, G Burg, ... Nature medicine 4 (3), 328-332, 1998	3886	1998
Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017	3526	2017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019	3008	2019
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016	2956	2016
A landscape of driver mutations in melanoma E Hodis, IR Watson, GV Kryukov, ST Arold, M Imielinski, JP Theurillat, ... Cell 150 (2), 251-263, 2012	2922	2012
Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015	2890	2015
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ... Science 350 (6257), 207-211, 2015	2699	2015
Genomic classification of cutaneous melanoma R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ... Cell 161 (7), 1681-1696, 2015	2657	2015
Improved survival with MEK inhibition in BRAF-mutated melanoma KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ... New England Journal of Medicine 367 (2), 107-114, 2012	2575	2012
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018	2550	2018
Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018	2405	2018
Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma D Schadendorf, FS Hodi, C Robert, JS Weber, K Margolin, O Hamid, ... Journal of clinical oncology 33 (17), 1889, 2015	2389	2015
Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018	2141	2018
TERT promoter mutations in familial and sporadic melanoma S Horn, A Figl, PS Rachakonda, C Fischer, A Sucker, A Gast, S Kadel, ... Science 339 (6122), 959-961, 2013	2047	2013
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018	2005	2018

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors